Pfizer’s Prevenar 13 gets US approval for adults
Health authorities of United States have approved the expansion of Pfizer Inc's Prevnar vaccine for use in adults 50 and older to fight pneumonia, meningitis and other diseases cause by pneumococcus...
View ArticlePfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in...
Pfizer Inc. issued the following statement in response to today's discussion by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the...
View ArticlePfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study...
Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and...
View ArticleTop-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease
Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years...
View ArticleSaint Louis University to participate in PPV23 vaccine trial for pneumonia
Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types...
View ArticleNIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial
Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other...
View ArticleEC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease
Pfizer Inc. announced today that the European Commission has approved expanding the use of the company's pneumococcal conjugate vaccine, Prevenar 13(pneumococcal polysaccharide conjugate vaccine...
View ArticleFDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older...
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent...
View ArticleResults from Pfizer’s Prevnar 13 Phase 3 study on HIV
Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197...
View ArticlePfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary...
Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])...
View ArticlePfizer's Prevenar 13 receives European approval to include adults for...
Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded...
View ArticleInfant vaccination against pneumonia helps protect elderly
Children who receive a vaccine to prevent blood and ear infections, appear to be reducing the spread of pneumonia to the rest of the population, especially their grandparents and other older adults.
View ArticleEuropean Commission approves updated label of Prevenar 13 for high risk...
Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13*...
View ArticleGenocea commences GEN-004 Phase 1 study to prevent pneumococcus infections
Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for...
View ArticleAstellas, ClearPath announce strategic partnership to develop vaccine for...
Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting...
View ArticlePrevalence of bacterial meningitis drops in the United States
Advances in the prevention and treatment of an often fatal condition called bacterial meningitis appear to be paying dividends in the United States, report infectious disease experts at The University...
View ArticleMedical advisory panel recommends new pneumonia vaccine for seniors
The experts expressed concern, however, that Medicare rules may hamper some people from getting the new vaccine if they have already had an older version. Also in drug issues, some patient advocates...
View ArticleImportant vaccines that should not be missed by adults, elders and pregnant...
Vaccines are an important part of routine healthcare for adults, seniors and women who are pregnant.
View ArticleOne-shot vaccine passes key preclinical test in newborn monkey models
Newborns are highly vulnerable to infections and don't respond optimally to most vaccines because their young immune systems typically mount weak antibody responses.
View ArticlePfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary...
Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])...
View Article